These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 16267003)

  • 21. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.
    Dupont PJ; Warrens AN
    Immunology; 2007 Jan; 120(1):133-9. PubMed ID: 17233740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
    Gastman BR; Atarshi Y; Reichert TE; Saito T; Balkir L; Rabinowich H; Whiteside TL
    Cancer Res; 1999 Oct; 59(20):5356-64. PubMed ID: 10537320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of Fas ligand does not confer immune privilege to a pancreatic beta tumor cell line (betaTC-3).
    Okamoto S; Takamizawa S; Bishop W; Wen J; Kimura K; Sandler A
    J Surg Res; 1999 Jun; 84(1):77-81. PubMed ID: 10334893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
    Huerta-Yepez S; Vega M; Garban H; Bonavida B
    Clin Immunol; 2006 Sep; 120(3):297-309. PubMed ID: 16784892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.
    Okada K; Komuta K; Hashimoto S; Matsuzaki S; Kanematsu T; Koji T
    Clin Cancer Res; 2000 Sep; 6(9):3560-4. PubMed ID: 10999744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
    Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human colon cancer cells express the functional Fas ligand.
    Ding EX; Hizuta A; Morimoto Y; Tanida T; Hongo T; Ishii T; Yamano T; Fujiwara T; Iwagaki H; Tanaka N
    Res Commun Mol Pathol Pharmacol; 1998 Jul; 101(1):13-24. PubMed ID: 9755840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
    Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
    Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fas-related apoptosis in gastric adenocarcinoma.
    Lim SC
    Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo.
    Houston A; Waldron-Lynch FD; Bennett MW; Roche D; O'Sullivan GC; Shanahan F; O'Connell J
    Int J Cancer; 2003 Nov; 107(2):209-14. PubMed ID: 12949796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
    Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
    Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
    Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
    Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
    Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.
    Mitsiades N; Yu WH; Poulaki V; Tsokos M; Stamenkovic I
    Cancer Res; 2001 Jan; 61(2):577-81. PubMed ID: 11212252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
    Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
    Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The "Fas counterattack": a mechanism for immune evasion in human hilar cholangiocarcinomas].
    Li Z; Zhang L; Zou S
    Zhonghua Yi Xue Za Zhi; 2002 May; 82(9):606-9. PubMed ID: 12133481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.
    Lee SH; Bar-Haim E; Goldberger O; Reich-Zeliger S; Vadai E; Tzehoval E; Eisenbach L
    Immunol Lett; 2004 Feb; 91(2-3):119-26. PubMed ID: 15019279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
    Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significant inhibition of human CD8(+) cytotoxic T lymphocyte-mediated xenocytotoxicity by overexpression of the human decoy Fas antigen.
    Kawamoto K; Tanemura M; Nishida T; Fukuzawa M; Ito T; Matsuda H
    Transplantation; 2006 Mar; 81(5):789-96. PubMed ID: 16534484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.
    Gopalan B; Litvak A; Sharma S; Mhashilkar AM; Chada S; Ramesh R
    Cancer Res; 2005 Apr; 65(8):3017-24. PubMed ID: 15833826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.